Skip to Content
Søg Menu

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

In this MEDtalk, Barbara Eichhorst, Associate Professor at the University Hospital Cologne, presents some of the most essential highlights from EHA Congress 2023 regarding first-line treatment for patients with CLL.
Barbara Eichhorst

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Paolo Ghia

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Paolo Ghia
EHA24CLL Play the Video 02:42
Alessandra Tedeschi

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

/ Alessandra Tedeschi
EHA24CLL Play the Video 01:52

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ BestPractice Nordic
ASH23CLL
Jeff P. Sharman

No Increased Risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Jeff P. Sharman
ASH23CLL Play the Video 1:45
Jeff P. Sharman

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

/ Jeff P. Sharman
ASH23CLL Play the Video 2:45

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

/ BestPractice Nordic
ASH23CLL
Peter Hillmen

New Standard of Care for Previously Untreated CLL

/ Peter Hillmen
ASH23CLL Play the Video 5:40

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

/ BestPractice Nordic
ASH23CLL
Back to top